Getting some money back no matter what the cost.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wooo Hoo! I'm hav'n me some foolaymanyawn tonight =D
I still hold 2 million shares. What's it worth today?
Yuppers!
On 11/06/07 I sold 8,500 shares at a loss
What about an award from the SEC and they send him the bill?
Thanks for the reply!
$3.7 million is a lot for one person, maybe they were big enough trades during one day to impact the stock price for me to have a loss.
MNTA: Question: FDA Chemist Pleads Guilty To Insider Trading
Q: Can I sue this guy to recover any loss the same time he was trading?
Is this stock still trading? looks a little dead around here. How Ya'll do'n?
What happened to DNDN last month?
Shhhhhhhhhh lol
How bout a $1 million bonus for each employee ;)
What is that all about?
Thanks!
Ive seen it a few times but not that long
MNTA: press release
June 21, 2011, 10:00 a.m. EDT
http://www.marketwatch.com/story/momenta-pharmaceuticals-ceo-craig-wheeler-named-ernst-young-entrepreneur-of-the-yearr-2011-new-england-award-winner-2011-06-21?reflink=MW_news_stmp
Momenta Pharmaceuticals CEO Craig Wheeler Named Ernst & Young Entrepreneur Of The Year(R) 2011 New England Award Winner
CAMBRIDGE, Mass., Jun 21, 2011 (GlobeNewswire via COMTEX) -- Momenta Pharmaceuticals, Inc. /quotes/zigman/92474/quotes/nls/mnta MNTA +2.26% , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its president and chief executive officer, Craig Wheeler, received the Ernst & Young Entrepreneur Of The Year(R) 2011 New England Award in the Biotechnology category. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Mr. Wheeler was selected by an independent panel of judges, and the award was presented at a gala event at the Renaissance Boston Waterfront Hotel on June 15, 2011.
Commenting on the award Mr. Wheeler noted, "While I am honored to be recognized, the award is truly a tribute to the years of hard work on the part of our talented and committed employees. Our team at Momenta is capable of great things, and I am honored to share this award with them."
As a New England award winner, Mr. Wheeler is now eligible for consideration for the Ernst & Young Entrepreneur Of The Year 2011 National Award. Award winners in several national categories, as well as the overall Ernst & Young Entrepreneur Of The Year National Award winner, will be announced at the annual awards gala in Palm Springs, California, on November 12, 2011. The gala is the culminating event of the Ernst & Young Strategic Growth Forum(R), the nation's most prestigious gathering of high-growth, market-leading companies, which will be held November 9-13, 2011.
The Ernst & Young Entrepreneur Of The Year Program celebrates its 25th anniversary this year. Past award winners have included Howard Schultz of Starbucks Coffee Company, Arthur M. Blank of AMB Group, LLC (The Home Depot, Atlanta Falcons), Pierre Omidyar of eBay, Inc., Ruth Fertel of Ruth's Chris Steak House, Inc., Maxine Clark of Build-A-Bear Workshop, Tom Adams of Rosetta Stone Inc., Matthew Szulik of Red Hat, Inc., and last year's national winner, Howard Lutnick, Chairman and CEO of Cantor Fitzgerald and BGC Capital Partners, Inc.
Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Program is pleased to have the Ewing Marion Kauffman Foundation as a national sponsor. The New England program sponsors are Boston magazine, J. Robert Scott, Marsh, Nixon Peabody LLP, RR Donnelley and Regan Communications Group.
About Ernst & Young Entrepreneur Of The Year(R)
Ernst & Young Entrepreneur Of The Year(R) is the world's most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential, and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 140 cities in more than 50 countries.
About Ernst & Young
Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 141,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.
Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit www.ey.com .
Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Momenta Pharmaceuticals
CONTACT: Beverly Holley
Director, Investor Relations
Momenta Pharmaceuticals, Inc.
bholley@momentapharma.com
617-395-5189
MNTA:News
US court dismisses Teva motion on Copaxone
Teva's motion for a summary judgement was part of its lawsuit to block Mylan's efforts to develop a generic version of Copaxone.
19 June 11 14:32, Shiri Habib-Valdhorn
The US District Court for the Southern District of New York has dismissed a motion for summary judgment on Copaxone filed by Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA). Teva filed the motion for a summary judgment finding of no inequitable conduct as part of its lawsuit to block efforts by Mylan Inc. (Nasdaq: MYL) its develop a generic version of Teva's brand drug Copaxone for the treatment of multiple sclerosis.
The court also set a start date of July 11, for the trial on Mylan's inequitable conduct affirmative defense. The trial on the remaining issues will begin on September 7.
Teva is suing Mylan, Momenta Pharmaceuticals Inc. (Nasdaq: MNTA), Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) unit Sandoz, and India's Natco Pharma Ltd. for patent infringement of Copaxone. Copaxone has $3 billion in annual sales. The defendants claim that Teva's conduct in registering the patents is inequitable and that it is attempting to win summary judgments.
Teva is also involved in legal proceedings against Watson Pharmaceuticals Inc. (NYSE: WPI), which wants to launch a generic version of the contraceptive Seasonique, produced by Duramed Pharmaceuticals Inc, a unit of Teva subsidiary Barr Pharmaceuticals, and marketed by Teva Women's Health. On Friday, an appeals court issued a preliminary injunction that prevents Watson from selling generic Seasonique until the US Court of Appeals for the Federal Circuit in Washington rules on whether sales should be halted further until it rules on a separate appeal by Duramed unit to block Watson’s generic version. Watson has until July 1 to respond.
Teva's share price fell 3.5% on Thursday and Friday on Nasdaq to $47.49, giving a market cap of $41.4 billion, and fell 4.4% by early afternoon on the TASE today to NIS 163.10.
Published by Globes [online], Israel business news - www.globes-online.com - on June 19, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
http://www.globes.co.il/serveen/globes/docview.asp?did=1000655606&fid=1725
You sill alive little buddie? =D
MNTA: Duke Health doctor under probe
Triangle Business Journal - by Jason DeBruyn
Date: Tuesday, May 31, 2011, 10:54am EDT
Related:Health Care
Enlarge Image
Steve Wilson
The main entrance to Duke University Hospital in Durham.
Related News
Funder boosts Centice’s drug technology
Paying Players
Duke grad builds financial services firm in hometown
Blue Cross brings on-site billing to Duke
Duke: Triangle could be smart grid hub
Duke Health pulmonary physician Dr. Victor F. Tapson has come under scrutiny by the U.S. Senate Committee on Finance after he allegedly lobbied the Food and Drug Administration for pharmaceutical company Sanofi-Aventis (NYSE: SNY) without disclosing a financial relationship he had with the drug maker.
In a report, the Senate committee shows that Sanofi tried to block the approval of generic drugs to compete with Lovenox, a blockbuster blood thinner that brought Sanofi $2.9 billion in sales in 2009.
Sanofi took advantage of the FDA’s citizen petition process, which allows individuals and experts to raise concerns about the alternatives and Tapson participated in a petition following encouragement from Sanofi, but did not disclose the more than $200,000 he received from Sanofi, the report states.
Additionally, the Society of Hospital Medicine and the North American Thrombosis Forum each lobbied against the generic drugs as well and received more than $2 million each from Sanofi, according to the Senate committee.
Tapson was not immediately available for comment Tuesday, but in an emailed statement to Duke University’s student newspaper, The Chronicle, he disputed many of the Senate committee’s findings. He says he had disclosed his relationship with Sanofi to the Senate committee in a March meeting and told members he had received consulting fees from the drug maker. He also challenges the $200,000 figure, saying that amount did not match his records or what he filed on his income tax form, according to The Chronicle.
He confirmed to The Chronicle that he did not make any reference to his financial connection in the petition sent in May.
Read more: Duke Health doctor under probe | Triangle Business Journal
http://www.bizjournals.com/triangle/news/2011/05/31/duke-health-doctor-under-probe.html
MNTA: Are they investigating if the Sanofi goon squad had a phantom account to short MNTA stock and cause the huge dips while doing what they just got investigated for?
Thanks!
We rich yet?
I don't trade it IOwn it*
*It as in shares
Hi Tom! Just having some fun with the guy. Besides I wanted to say hello to Dew. I was counting on Dew PMing me I can't PM since I won't give them any of my money ever again =D I been here since iHub chat.
Do you know who I am Pal???
Dew, been away. Any reason why MNTA share price on the up trend?
Change the laws for the common good of our Country and don't hire these people. I bet some of that cash got kicked back to his own country's government.
Hello iOwn 250,000 shares of CMKX. I have it hanging on my wall framed in certificate form. How much is it worth now?
Thanks!
Hey Yore! What's news?
Hey Matt how you been superstar =D
OT:Not sure if you know this but the rail yard in Boston off exit 18 on the mass pike will be made into Dorms and Lab space.
They say there will be a renaissance of the railroads in the future and there is a lot of invested interest. What's going to happen when the economy goes full swing when there is no freight service in Boston?
You think the big dig and surrounding highways are clogged, wait till people start buying and building. I don't think anyone in the Boston area knows about this. Its all going to be trucked in.
Will Paying Whistle-Blowers for Tips Lead to More SEC Crackdowns?
By BRUCE KENNEDY
Posted 6:45 PM 08/09/10 Investing
EmailMore
The feds know that money talks, but they may get more than they bargained for. According to the Financial Times (subscription required), the new Dodd-Frank financial reform act includes a provision to offer lucrative rewards to people who alert authorities to securities and other types of financial fraud. People who are able to provide information that leads to a successful SEC enforcement action will be entitled to 10% to 30% of any penalties collected over the $1 million mark, the newspaper said.
The possibility of a seven-figure reward "reflects the high quality of whistleblower we hope to get -- people within a company, broker or other regulated firm that we might not have heard from before," the Securities and Exchange Commission's Stephen Cohen told the FT.
Cohen says the SEC expects "a tremendous response" from Wall Street insiders. But at least one long-term observer of the system is skeptical.
Gaming the System?
"It's good to have people reporting some type of malfeasance, either corporate or government wrongdoing. You want to encourage people to report," says Dr. Stephen Martin, a clinical professor with the department of business ethics and legal studies at the University of Denver's Daniels College of Business.
But for Martin, who has also worked as a corporate compliance officer and federal prosecutor, providing incentives for such tip-offs can encourage frivolous or unjustified claims.
"The system might be played by people as well as lawyers who are working with whistle-blowers," he says, "to encourage them to go after some type of report, to try and get some kind of big settlement out of it. The real key is not the quantity of reporting [of fraud]. You want quality reporting so the government can use their resources in the best way possible, to really uncover what are the major crimes, frauds, issues -- not chasing down every possible lead, because they don't have the resources to do it."
And while it's "perfectly legitimate" for the Obama Administration to go after such fraud, Martin doubts if it will have any long-term effect on Wall Street's notoriously flexible ethics.
"I think it's something the government [must do] to show it's serious," he says. "I don't know that it really changes behavior on Wall Street. People make decisions based on short-term benefit and greed, financial incentive. They don't worry really about the downside, long-term impact. If they did, you wouldn't see these [financial collapses] happening, and you wouldn't see them repeat. I don't think most people who make these decisions in Wall Street are really worried about whether a whistleblower is going to get 10% or not. For them it doesn't really enter the calculus of when they're making those kinds of decisions. Of course, they'll tell you they weren't doing anything wrong to start with."
What is the reason for the drop? I went to sleep and this stock was in positive territory. I go to sleep and it crashes, what happened?
Would they give one to Teva also if they got approved?
Any word on the Markman hearing?
MNTA: The hearing is scheduled on August 17 to rule on a preliminary injunction.
Can we expect significant stock price movement after that date?
Any word on the Markman hearing?
Check out this article from TEVA LOL!
http://www.globes.co.il/serveen/globes/docview.asp?did=1000577536&fid=1725
Good luck! Keep an eye on that pre-market
I have Google Alerts for MNTA. I have gotten 100's of articles from News papers and magazines all over the world. I think no one noticed that it was approved yesterday. Wait till the market opens Monday Morning. BOOM! To the Moon Baby!
Has anyone called the company to ask when or if they are going to file suit to get the FDA moving on the approval?
MNTA: Option trading and stock price should be interesting today =D
http://www.zacks.com/research/get_news.php?id=197l6022
http://www.dailyfinance.com/story/investing/the-biggest-winners-in-the-financial-regulation-overhaul/19556255/
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52341707
MNTA Sanofi's Secret Weapon
Sanofi's Secret Weapon
http://www.fool.com/investing/high-growth/2010/06/24/sanofis-secret-weapon.aspx
Brian Orelli
June 24, 2010
In the never-ending battle to bring generic versions of sanofi-aventis' (NYSE: SNY) Lovenox to market, Sanofi has a secret weapon: doctors who have asked the Food and Drug Administration not to approve generic versions because of safety concerns. Lovenox is a complex heparin-based molecule, and two doctors groups and a medical researcher think the only way to prove generic versions are the same is to run clinical trials.
There's just one problem. According to The Wall Street Journal, the people advocating on Sanofi's behalf have received financial support from the company in the past. How much the FDA takes their opinion into consideration remains to be seen.
This isn't small potatoes, either; Lovenox registered about $2.2 billion worth of sales in the U.S. last year. With only three companies, Amphastar Pharmaceuticals, Teva Pharmaceutical (Nasdaq: TEVA) and Momenta Pharmaceuticals (Nasdaq: MNTA), vying for approval, the generic-drug price is likely to be fairly close to that of the branded drug.
Of course, that's if the FDA ever signs off on an approval. Unlike for branded drugs, the agency doesn't have any mandated goals for deciding upon generic-drug marketing applications. It's had Teva's and Amphastar's applications since 2003 and Momenta's since 2005. Motley Fool Rule Breakers pick Momenta might seem like the underdog, but it has help from generic-drug giant Novartis (NYSE: NVS), and Momenta helped the FDA sort out Baxter's (NYSE: BAX) contaminated heparin issues back in 2008, which might earn it some brownie points.
The bigger issue for the companies may be whether doctors will prescribe generics. Sure, experts with financial ties to Sanofi probably aren't the most unbiased of sources, but how concerned will other physicians be about the use of generic Lovenox even if the FDA signs off? Pharmacists are generally allowed to substitute generics at will, but most prescription forms have a box to override that power.
That check box could become Sanofi's next secret weapon.
--------------------------------------------------------------------------------
Legal Information. © 1995-2008 The Motley Fool. All rights reserved.
Eh, maybe MNTA next